ABSTRACT We have studied the efficacy of three devices designed to conserve oxygen delivered to patients with hypoxic chronic bronchitis and emphysema. Devices A and B are valve systems, which deliver oxygen only during inspiration. Device C is a modified nasal prongs system incorporating a "moustache reservoir" (Oxymizer, Chad Therapeutics Inc, Woodland Hills, California), which is claimed to produce a higher arterial oxygen saturation (Sao2) from a given flow of oxygen than does continuous delivery through nasal prongs. Devices A and B were found to give the same oxygen saturation as continuous flow oxygen, but only device B reduced the flow of oxygen significantly (p < 0-01). The flow characteristics of device A were likely to be the cause of this failure to conserve oxygen. Device C produced a higher mean rise in Sao2 than did standard nasal prongs at all oxygen flow rates, and was able to achieve the same rise in Sao2 as standard nasal prongs with a small (25-33%) saving in oxygen delivery. There was, however, considerable variation between patients in the oxygen saving efficiency of device C, with little or no oxygen saving in seven of the 12 patients studied.
automatically if inspiration is not detected over a 17 second period, delivering oxygen to the patient for a predetermined time. Both the 17 second delay and the oxygen delivery time are adjustable. This device, which is a prototype, measures 12 x 10 x 7 cm and weighs 1.3 kg. The suppliers (Glasrock Home Health Care, Brentford, Middlesex) intend to produce a final version that is smaller and lighter and should cost around £150.
Device B works on a principle similar to that of device A but delivers a short burst of oxygen at a high flow rate at the beginning of inspiration. This device is the DOC (Demand Oxygen Controller), a demand type valve incorporated into a portable liquid oxygen system (Pulsair I), which is commercially available in the United States. (DOC and Pulsair are registered trade marks of Cryo/2 Corporation, Fort Pierce, Florida.) Device C is a modified nasal prongs system ("Oxymizer," Chad Therapeutics Inc, Woodland Hills, California), which incorporates a "moustache" oxygen reservoir that stores oxygen during expiration, so that a bolus of 20 ml of about 85% oxygen is inhaled at the beginning of inspiration. It has been To assess device C each patient breathed oxygen on two occasions, one with device C and the other with standard nasal prongs. The order of these two studies was assigned randomly. Oxygen was delivered from a 120 ft3 (3400 1) cylinder, a calibrated rotameter being used that could measure to 0.05 1/ min (AP6222 flowmeter, Rotameter Manufacturing Co Ltd) at 0.5, 1.0, 1.5, 2.0, and 3.0 I/min. At (fig 1) .
In all 12 patients device A achieved perfect synchronisation with respiration during resting tidal breathing, but at respiratory frequencies greater than 25 breaths/min the device intermittently failed to trigger. Studies in the normal subject confirmed that both device A and device B achieved perfect synchronisation during resting breathing, through the nose or mouth, but intermittently failed to trigger at respiratory frequencies greater than 25 breaths/min. Both devices continued to trigger at tidal volumes of 100 ml and below, but an absolute Patients with hypoxaemic chronic bronchitis and emphysema commonly suffer profound hypoxaemia during sleep, and these episodes may be related to hypoventilation or changes in the ventilationperfusion relationship (or both). An oxygen conserving device used in these patients should not exacerbate this, and since the three devices we studied continue to deliver oxygen even during hypoventilation this should not be a problem, though clinical studies during sleep are needed to confirm this.
We conclude that in 12 patients with hypoxaemia and severe airflow obstruction device A was inefficient in conserving oxygen, though efficiency could be improved by altering its flow characteristics. Device B did conserve oxygen, yet maintained arterial oxygen saturation. Device C consistently achieved a greater rise in Sao2 than standard nasal prongs at the same oxygen flow rate in five of 12 patients, so saving some oxygen, but did not do this in seven similar patients.
Oxygen conservation can thus be achieved by some of these methods but further studies are needed to determine which system is likely to produce maximum cost effectiveness in long term clinical use. 
